STOCK TITAN
  1. Home
  2. Sec-filings
  3. CVKD
  4. [Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Cadrenal (CVKD) CEO Pham sells 4,126 shares, retains large stake via trust

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cadrenal Therapeutics Chairman and CEO Quang X. Pham reported open-market sales of 4,126 shares of Common Stock at weighted average prices around $3.16–$3.18 per share. The sales on June 16–17, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2025.

After these transactions, Pham holds 128,589 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power. The reported sales represent a small portion of his overall reported holdings and do not involve any derivative exercises.

Positive

  • None.

Negative

  • None.

Insights

Cadrenal’s CEO sold a small share block under a pre-set 10b5-1 plan.

Chairman and CEO Quang X. Pham executed open-market sales totaling 4,126 Cadrenal Therapeutics shares at weighted average prices slightly above $3 per share. The filing notes these trades were made pursuant to a Rule 10b5-1 plan adopted on September 25, 2025, indicating they were pre-scheduled.

Following the sales, Pham still holds 128,589 shares directly and 200,000 shares indirectly via The PVBQ Living Trust, where he has sole voting and dispositive power. This suggests the transactions reduced, but did not materially alter, his overall equity exposure, and there are no remaining derivative positions disclosed.

The pre-planned nature and modest size relative to reported holdings make this look like routine liquidity management rather than a strong signaling event. Future ownership updates will appear in subsequent filings if additional trades occur.

Insider Pham Quang X
Role Chairman, CEO and Interim CFO
Sold 4,126 shs ($13K)
Type Security Shares Price Value
Sale Common Stock 513 $3.16 $2K
Sale Common Stock 3,613 $3.18 $11K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 128,589 shares (Direct, null); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)
Footnotes (1)
  1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.04 through $3.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.14 through $3.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
Total shares sold 4,126 shares Open-market sales on June 16–17, 2026
June 17 sale size 513 shares Common Stock sold at $3.16 per share
June 16 sale size 3,613 shares Common Stock sold at $3.18 per share
Direct holdings after trades 128,589 shares Common Stock held directly after June 17, 2026
Indirect trust holdings 200,000 shares Common Stock held through The PVBQ Living Trust
Net shares sold 4,126 shares Net-sell direction in transaction summary
Price range batch 1 $3.04–$3.37 Weighted average sale price range per footnote
Price range batch 2 $3.14–$3.20 Weighted average sale price range per footnote
Rule 10b5-1 trading arrangement regulatory
"shares of the Issuer's common stock sold ... in accordance with a Rule 10b5-1 trading arrangement"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale" with transaction code "S""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"direct_or_indirect: "I" and nature_of_ownership: "The PVBQ Living Trust""
dispositive power regulatory
"has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pham Quang X
(Last)(First)(Middle)
C/O CADRENAL THERAPEUTICS, INC.
822 A1A NORTH, SUITE 306
(Street)
PONTE VEDRA FLORIDA 32082
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chairman, CEO and Interim CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/16/2026S3,613(1)D$3.18(2)129,102D
Common Stock06/17/2026S513(1)D$3.16(3)128,589D
Common Stock200,000IThe PVBQ Living Trust(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.04 through $3.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.14 through $3.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
/s/ Quang X. Pham06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Cadrenal Therapeutics (CVKD) report for Quang X. Pham?

Cadrenal Therapeutics reported that Chairman and CEO Quang X. Pham sold 4,126 shares of Common Stock in open-market transactions at weighted average prices slightly above $3 per share. The trades occurred on June 16 and 17, 2026, and were reported on Form 4.

Were Quang X. Pham’s Cadrenal (CVKD) share sales made under a Rule 10b5-1 plan?

Yes. The filing states Pham’s sales were executed under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Such plans pre-schedule trades, reducing the significance of transaction timing as a signal of the insider’s short-term view on the stock.

How many Cadrenal Therapeutics (CVKD) shares does Quang X. Pham hold after these transactions?

After the reported sales, Pham holds 128,589 Cadrenal Therapeutics shares directly. He also has indirect ownership of 200,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power over those shares.

What prices were received in Quang X. Pham’s recent Cadrenal (CVKD) stock sales?

The filing reports weighted average sale prices. One batch of shares was sold at approximately $3.16 per share, with trades ranging from $3.04 to $3.37. Another batch averaged about $3.18 per share, with individual trades between $3.14 and $3.20.

Does Quang X. Pham have any Cadrenal (CVKD) derivative positions after this Form 4?

No derivative positions are listed in the derivative summary of the Form 4. The reported activity involves only non-derivative Common Stock transactions, with no stock options, warrants, or similar instruments disclosed as outstanding in this particular filing.

What is The PVBQ Living Trust’s role in Quang X. Pham’s Cadrenal (CVKD) holdings?

The PVBQ Living Trust holds 200,000 Cadrenal shares as an indirect position for Pham. He is trustee with sole voting and dispositive power over these shares, and the trust’s sole beneficiary is his child, according to the Form 4 footnotes.